Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Mercia Asset Management Plc LSE:MERC London Ordinary Share GB00BSL71W47 ORD 0.001P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 21.50 21.00 22.00 21.50 21.50 21.50 20,023 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 10.7 2.6 0.9 25.0 95

Mercia Asset Management Share Discussion Threads

Showing 1001 to 1025 of 1025 messages
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
DateSubjectAuthorDiscuss
20/10/2020
17:17
Bear in mind the portfolio covid provisions for companies thought to be most affected were made at the start of the spring lockdown and the company thinks they were overly conservative. As provisions are removed up to 3.5p/share would be added back to NAV and further uplift can be expected for companies that have prospered due to covid.
columbarius
19/10/2020
09:54
A good outcome in percentage terms is this sale of MERC's 4% stake in Clear Review but the proceeds of £1 million are not significant against a market cap of £97m. More significant is that MERC has done well for its managed funds on their holdings. What we really need to see is some action in nDreams, MERC's largest investment. Even so, this modest sale helps to justify the NAV claimed in recent accounts.
varies
06/10/2020
19:31
hTtps://www.mercia.co.uk/casestudy/abingdon-health Further to post 836 Abingdon Health may pursue an IPO following today's excellent news of a big UK government contract for rapid covid-19 antibody tests. I see this as the first of many such contracts in the UK and worldwide. Abingdon have also developed an app to support the tests. Goodness knows we need one. Mercia might use an IPO as an opportunity to promote Abingdon to its balance sheet. They recently indicated something along those lines. At the very least Mercia will have top notch PR emphasising their role in promoting and developing world class companies in the UK regions. This story has legs as Abingdon will have the gold standard for rapid tests as approved by the University of Oxford. hTtps://www.abingdonhealth.com/uk-government-confirms-order-1m-covid-19-rapid-antibody-tests
columbarius
06/10/2020
13:34
you're welcome varies. I think based on the potential and that nDreams are churning out award winning games a £46m valuation seems reasonable. VR will be huge in the future - people will be wandering around in virtual worlds, built on blockchain and spending cryptocurrency to own chunks of virtual real estate. I'd say on a 5-year time horizon they will be very successful. But to do so...enough people will need to have the kit. Watch 'ready player one' the recent film by Stephen Spielberg for a flavour!
gb904150
06/10/2020
10:17
GB904150 Thank you very much for taking the trouble to explain the reality of VR games to me. I had no idea that the headset required cost £400 + more for the add-on. MERC tells us little about nDreams and I assume that the £16m attributed to its 36% stake is Book Value. In other words this is the cost and MERC has seen no need to mark it down.
varies
05/10/2020
19:50
hi varies, I'm no expert but nDreams and FDEV are at quite different stages i'd say. hTTps://www.frontier.co.uk/investors The presentation shows them at £76m revs. £16m op profit. £31m EBITDA. 560 people from 32 nationalities. Established 26+ years with sales of multiple millions of units of top games. nDreams I would hazard a guess are much smaller - perhaps a 10th of that? Probably loss making but with immense potential for the future. VR gaming and VR experiences in general are going to be massive. nDreams are a specialist in that and their game - Phantom: Covert ops has very impressive reviews from gaming mags. So, huge growth area....but VR is only as good as how many people out there can afford to shell out for VR headsets. Oculus go helped that a lot - bringing the investment down something more reasonable. Vive Cosmos costs £699 Oculus Rift S costs £399 Or perhaps when PS5 comes out in November a VR options (VR2) comes out in early 2021 to bring it to the masses. hTTps://www.techadvisor.co.uk/news/game/playstation-vr-2-3779746/ You're still looking at about £400 for PS5 plus £300 for the VR add-on. It's not exactly mass market prices...so it's still very top end focused. So although it might be brilliant (i've not tried it but am tempted) it doesn't have a large addressable market yet.
gb904150
05/10/2020
12:23
An article in yesterday's Sunday Telegraph on Frontier Developments, now cap. at £1,000 million has prompted me to look at nDreams. MERC holds 36% of nDreams and values this at £16m implying a value of £44m for the company. This is MERC's most highly valued direct investment in a portfolio valued at £91m. The nDreams web-site contains no financial figures at all that I can see but does list these Virtual Reality titles : Shooty Fruity, Phantom Covert Ops, the Assembly, Danger Goat and Perfect. I know nothing of computer games but I can find no mention of these on VR sales web-sites. Does anyone subscribing to this thread understand such things ? I would be very interested to learn more and whether nDreams is indeed as succesful as MERC suggests.
varies
25/9/2020
17:27
Ex-chairman and current non-exec Ray Chamberlain has backed the management by upping his beneficial interest to 15%. Hard cash investment means more to me than whinges about past decisions. As far as I'm concerned management are making good progress against the stated aims of making a profit from fund management, increasing assets under management to £1 billion and making the portfolio business self-sustaining (evergreen). I'm guessing the next cash realization will be an IPO for one of the managed fund businesses. If I'm right it won't have a direct impact on the MERC share price but it will add to their reputation.
columbarius
25/9/2020
12:03
The simple fact is that these guys didn't set up this business to make private investors rich. I have noticed quite a lot of comments that were rather over the top and could never understand them. I looked at the business model and the assets and thought "that'll do me" I have added since then and not seen anything to change my mind. The share placing at 25p had everyone screaming but you could've bought any amounts after the placing at less than 25p and they certainly they knew what they wanted the money for. Simon Thompson threw the toys out the pram but I didn't think he gave proper weighting to the fact that the business opportunity came up and they wanted to do the deal. The placing wasn't handled well but it wasn't anything like as major an issue as Thompson and some here made out. Those people with a very low opinion of this management must be very happy today for if they are as self serving as some believe then things must really be going well. If I join the cynical group then perhaps they are getting close to a major cash realisation from their portfolio......just a thought.
pavey ark
25/9/2020
10:32
The fact they have put their hands in pocket to buy some is a booster. Perhaps it will/has changed but until now the business model looked fine, the management less so. Lets see going forward.
p1nkfish
25/9/2020
10:01
I've noticed some emotion on this thread and it's likely to have affected decision making. If you don't like a company it's best to sell and move on to something that interests you.
columbarius
25/9/2020
09:27
Wan, sorry, I didn't see what should have been your farewell post..."I'm out". 24/9/2020. I have no comment or judgement to make on your decision to sell...each to his own...however your comment today was silly and rather petty.
pavey ark
25/9/2020
09:12
OXGENE, based in Oxford, is a biotechnology company specialising in gene therapy, gene editing and antibody discovery that delivered a third consecutive year of 100%+ revenue growth, more than doubling revenues in its financial year ended 30 April 2020. This continued growth has been fuelled by a combination of strategic licensing agreements and service delivery projects, including a strategic partnership with Fujifilm Diosynth Biotechnologies. The company's continued growth has been recognised recently by The Sunday Times' Fastest Growing Tech 100 at position 19. 18/9/2020 Hmmmmm ?....wan..."good luck all" I for one think it's important to make your position clear and for the absence of doubt I hold quite a few of these. Historical figures, correct or not, are hardly the main point when dealing with a company in the biotech sector. Anyone buying Oxygen would look at the advantages they bring and the money that can be made from these advantages.
pavey ark
25/9/2020
09:07
Good to see the buys. Onward.
p1nkfish
25/9/2020
09:06
I don’t think it is acceptable for Mercia to just state that all AGM items were duly passed. Shareholders should expect to see the numbers of votes for and against each item. https://otp.tools.investis.com/Utilities/PDFDownload.aspx?Newsid=1418402
jane deer
25/9/2020
08:57
Oxygen looks very good but ndreams could be even bigger.....either would double the share price if they were sold or floated.....as this would point up the potential in the rest of the portfolio. The management here have come in for criticism but they have done/are doing everything they said they would do........including investing in the company. As usual private investors have taken the share price as a reflection of management's effort/abilities and that is seldom the case.
pavey ark
25/9/2020
08:48
Just to add that, whilst I am an enthusiastic supporter of British technology/business etc, Oxgene's last reported revenues were apparently £2m after an 100% increase, which cooled my enthusiasm somewhat. I genuinely hope this all comes good for investors. Good luck all!
wan
25/9/2020
08:21
Agreed SEV. Mercia's life sciences holdings look very promising. I'm particularly interested in Oxgene.
columbarius
25/9/2020
07:51
Good to see five Directors adding further share purchases to their personal stakes in Mercia yesterday, including one for 1,200,000 shares at 20p. Very positive news. https://www.investegate.co.uk/mercia-asset-mgt-plc--merc-/rns/director-pdmr-dealings/202009250700030714A/
sev22
24/9/2020
19:07
https://uk.tradingview.com/symbols/LSE-MERC/technicals/
sev22
24/9/2020
16:32
Ok . Good!
robsy2
24/9/2020
15:08
I think you're mistaken Robsy2. £658m is in long term funds. Including the balance sheet, they manage c.£800m as announced with the finals and re-iterated today.
columbarius
24/9/2020
12:05
I thought there had been a change of thought when they all bought in recently... gave me hope but looks to be a false dawn D
dennisbergkamp
24/9/2020
08:49
I'm still in but have to agree about management and am considering options. I hope I'm wrong, often am, but if not that something changes.
p1nkfish
24/9/2020
08:39
I'm out. Deciding, amongst other things, including past events, that the management are so far up their own backsides and those of the fund managers, that private investors, are at best, an irritant. Should Mercia really be listed? Perhaps that creates opportunity, but I cannot wait any longer when decent opportunity is available elsewhere, opportunity with a degree of clarity that seems to escape Mercia (perhaps that's intentional?).
wan
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
ADVFN Advertorial
Your Recent History
LSE
MERC
Mercia Ass..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201022 15:35:17